In clinical trials, tafenoquine plus chloroquine reduced P vivax recurrence by 70% compared with chloroquine plus placebo,4 with similar recurrence-free efficacy to chloroquine plus 14-day primaquine.4, 5 Both primaquine and tafenoquine can cause haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency, which might lead to acute haemolytic anaemia; therefore, G6PD testing is required before administration of these drugs.6, 7. Here, G6PD is linked to non-autoimmune hemolytic anemia.